MaxCyte, Inc.
MXCT
$2.79
-$0.05-1.76%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -6.44% | 19.85% | 11.69% | 6.80% | -6.72% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -6.44% | 19.85% | 11.69% | 6.80% | -6.72% |
Cost of Revenue | 49.73% | 35.56% | -0.64% | 2.18% | -6.98% |
Gross Profit | -13.73% | 17.63% | 13.53% | 7.44% | -6.68% |
SG&A Expenses | -1.21% | 9.80% | 16.04% | 20.73% | 28.24% |
Depreciation & Amortization | 3.96% | 10.28% | 20.89% | 38.37% | 57.64% |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 0.27% | 8.23% | 12.69% | 17.80% | 25.08% |
Operating Income | -6.00% | 1.20% | -13.70% | -30.28% | -76.53% |
Income Before Tax | -8.26% | 4.59% | -8.56% | -20.34% | -60.89% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -8.26% | 4.59% | -8.56% | -20.34% | -60.89% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -8.26% | 4.59% | -8.56% | -20.34% | -60.89% |
EBIT | -6.00% | 1.20% | -13.70% | -30.28% | -76.53% |
EBITDA | -6.24% | 2.17% | -13.09% | -29.72% | -78.93% |
EPS Basic | -6.53% | 5.97% | -7.14% | -18.72% | -58.54% |
Normalized Basic EPS | -6.58% | 5.94% | -7.20% | -18.72% | -58.45% |
EPS Diluted | -6.53% | 5.97% | -7.14% | -18.72% | -58.54% |
Normalized Diluted EPS | -6.58% | 5.94% | -7.20% | -18.72% | -58.45% |
Average Basic Shares Outstanding | 1.53% | 1.47% | 1.48% | 1.50% | 1.57% |
Average Diluted Shares Outstanding | 1.53% | 1.47% | 1.48% | 1.50% | 1.57% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |